Guest post by Hamish McDougall, Reporter at BioPharm Insight
BioPharm Insight’s (BPI) editorial neurology report highlights physicians’ renewed interest in amyloid reducing therapies for Alzheimer’s disease modification, the most notable from Biogen in Phase Ib. Meanwhile, multiple symptomatic AD treatments targeting cognitive deficits, psychosis and agitation/aggression are still being supported by physicians given the stark unmet need.
In Parkinson’s disease, several symptomatic drug approvals are expected in the next year, while earlier stage disease modifying therapies targeting alpha-synuclein will likely face trial challenges despite growing evidence supporting this approach. Elsewhere in the movement disorders space, Phase II-III VMAT2 inhibitors for tardive dyskinesia herald a promising future, while in muscular dystrophy, all eyes are on exon skipping drugs and how regulators may react to mixed data.
BioPharm Insight’s Neurology Report is a compilation of investigative news articles covering drug development across the therapeutic area, please click here for the full report. To request a free trial with BPI, please click here.
Meet Biogen and other potential partners at BioPharm America™ in Boston this September.